| 2.33 -0.15 (-6.05%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.17 |
1-year : | 3.45 |
| Resists | First : | 2.71 |
Second : | 2.96 |
| Pivot price | 2.68 |
|||
| Supports | First : | 2.31 |
Second : | 1.93 |
| MAs | MA(5) : | 2.47 |
MA(20) : | 2.7 |
| MA(100) : | 2.95 |
MA(250) : | 3 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.1 |
D(3) : | 29 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 5.38 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CATX ] has closed below the lower bollinger band by 2.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CATX ] is to continue within current trading range. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.47 - 2.49 | 2.49 - 2.5 |
| Low: | 2.29 - 2.3 | 2.3 - 2.32 |
| Close: | 2.31 - 2.33 | 2.33 - 2.35 |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Wed, 14 Jan 2026
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets
Tue, 13 Jan 2026
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat
Mon, 12 Jan 2026
Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView — Track All Markets
Mon, 12 Jan 2026
New targeted radiation treatments show durable cancer control in study - Stock Titan
Fri, 09 Jan 2026
Experimental targeted radiation shows tumor shrinkage in early trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|